Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2010
10/05/2010US7807371 Methods of selecting dopaminergic neuron proliferative progenitor cells using Lrp4/Corin markers
10/05/2010US7807170 Modulating an immune response in a subject by administering an effective amount of a lymphocyte differentiation factor; antiinflammatory agents
10/05/2010US7807167 using an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin; treatment of multiple sclerosis or inflammatory disease of the gastrointestinal tract
10/05/2010US7807157 Monoclonal antibodies and use thereof
10/05/2010US7807142 comprising interleukin-2 (IL-2); using an amino acid base sufficient to decrease aggregate formation of the polypeptide during storage of the composition, and a buffering agent ; mixture with amino acid and buffer
10/05/2010CA2441331C Bicyclic guanidine derivatives and therapeutic uses thereof
10/05/2010CA2434900C New use of iloperidone
10/05/2010CA2425218C Pharmaceutical solutions of modafinil compounds
10/05/2010CA2394579C Combination of an ergoline and riluzole for preventing and treating motor neuron diseases
10/05/2010CA2367138C Anti-inflammatory uses of manzamines
09/2010
09/30/2010WO2010111574A1 Compounds as cannabinoid receptor ligands
09/30/2010WO2010111573A1 Compounds as cannabinoid receptor ligands
09/30/2010WO2010111572A1 Compounds as cannabinoid receptor ligands
09/30/2010WO2010111527A1 Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
09/30/2010WO2010111522A2 Mesenchymal stem cells producing inhibitory rna for disease modification
09/30/2010WO2010111353A1 N-substituted piperidine derivatives as serotonin receptor agents
09/30/2010WO2010111136A2 Aliskiren modulation of neurogenesis
09/30/2010WO2010110923A2 Prophylactic and therapeutic treatment of alzheimer's disease
09/30/2010WO2010110755A1 Therapy for promoting cell growth
09/30/2010WO2010110647A1 Aurones as estrogen receptor modulators and their use in sex hormone dependent diseases
09/30/2010WO2010110646A1 Aurones as selective pde inhibitors and their use in neurological conditions and disorders
09/30/2010WO2010110552A2 Composition for prevention or treatment of insomnia
09/30/2010WO2010110479A1 Activator for peroxisome proliferator-activated receptor
09/30/2010WO2010110440A1 Novel therapeutic agent for cognitive impairment
09/30/2010WO2010110439A1 Composition for regulating autonomic nervous activity and method for regulating autonomic nerve
09/30/2010WO2010110408A1 Dna vaccine for alzheimer's disease
09/30/2010WO2010110400A1 Heterocyclic compound
09/30/2010WO2010110361A1 Method for producing bicyclic γ-amino acid derivative
09/30/2010WO2010110018A1 Coated solid preparation
09/30/2010WO2010109318A1 Process for the preparation of herbal extract of cassia tora leaves for treating anxiety disorders
09/30/2010WO2010109287A1 Fused pyrimidine-dione derivatives as trpa1 modulators
09/30/2010WO2010109150A1 Derivatives of 3-alkoxy-4,5-diarylthiophene-2-carboxamide, preparation thereof, and therapeutic use thereof
09/30/2010WO2010109148A1 Therapeutic uses of quinazolinedione derivatives
09/30/2010WO2010109050A1 Cromenopyrazole derivatives as cannabinoid receptor ligands
09/30/2010WO2010109008A1 Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones
09/30/2010WO2010109005A1 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
09/30/2010WO2010089510A3 Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
09/30/2010WO2010077852A3 Method of inducing cleavage of amyloid precursor protein to form a novel fragment
09/30/2010WO2010068483A3 Mlk inhibitors and methods of use
09/30/2010WO2010056075A3 Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases
09/30/2010WO2010017626A9 Compositions comprising terpene compounds for treating negative sensory phenomena
09/30/2010WO2010017216A8 Mesenchymal stromal cell populations and methods of isolating and using same
09/30/2010WO2009127949A8 4- [3- (aryloxy) benzylidene] -3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
09/30/2010US20100249243 Novel beta-hydroxyketones and beta-alkoxyketones with estrogenic activity
09/30/2010US20100249242 Method of reducing neuronal cell damage
09/30/2010US20100249225 C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for the Treatment of Anxiety Disorders
09/30/2010US20100249223 New use for cannabinoid-containing plant extracts
09/30/2010US20100249217 Modulators of pharmacological agents
09/30/2010US20100249208 Novel Methods and Models for Rapid, Widespread Delivery of Genetic Material to the CNS Using Non-Viral, Cationic Lipid-Mediated Vectors
09/30/2010US20100249207 Synthesis of pyrrolidine compounds
09/30/2010US20100249206 Modified lysine-mimetic compounds
09/30/2010US20100249203 Compounds that inhibit trpv1 and uses thereof
09/30/2010US20100249198 (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
09/30/2010US20100249196 Novel Salt Forms Of (2S)-(4E)-N-Methyl-5-[3-(5-Isopropoxypyridin)yl]-4-Penten 2-Amine
09/30/2010US20100249189 Nitric oxide donor compounds
09/30/2010US20100249188 Prediction of qt prolongation based on snp genotype
09/30/2010US20100249183 Therapeutic use of n-(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives
09/30/2010US20100249177 Compositions and methods for treating middle-of-the-night insomnia
09/30/2010US20100249176 Heterocycle amide t-type calcium channel antagonists
09/30/2010US20100249170 Intranasal compositions
09/30/2010US20100249167 Alkylsulfonyl-2,3-dihydrospiro[indene-1,4'-piperidine] analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
09/30/2010US20100249165 Pdz domain modulators
09/30/2010US20100249164 Modulation of sleep with nr2b receptor antagonists
09/30/2010US20100249163 Renin inhibitors
09/30/2010US20100249161 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes
09/30/2010US20100249159 Rho-kinase inhibitors
09/30/2010US20100249158 Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
09/30/2010US20100249150 Stable pharmaceutical composition of freeze-dried tetrodoxin powder
09/30/2010US20100249149 Inhibitors of Protein Kinases
09/30/2010US20100249144 Substituted piperazines as cb1 antagonists
09/30/2010US20100249136 Organic compounds
09/30/2010US20100249129 Compounds as cannabinoid receptor ligands
09/30/2010US20100249128 Novel 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives
09/30/2010US20100249124 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
09/30/2010US20100249118 Compounds and methods for kinase modulation, and indications therefor
09/30/2010US20100249107 Biomarkers for Alzheimer's Disease Progression
09/30/2010US20100249106 Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds
09/30/2010US20100249105 Indole and indoline derivatives and methods of use thereof
09/30/2010US20100249100 Quinazolines useful as modulators of ion channels
09/30/2010US20100249098 Oxypiperidine derivatives and methods of use thereof
09/30/2010US20100249095 Substituted Spiro-amide Compounds
09/30/2010US20100249093 Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators
09/30/2010US20100249090 Neurotherapeutic composition and method therefor
09/30/2010US20100249087 Compounds as cannabinoid receptor ligands
09/30/2010US20100249086 Compounds As Cannabinoid Receptor Ligands
09/30/2010US20100249085 Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
09/30/2010US20100249084 Substituted pyrimidines as adenosine receptor antagonists
09/30/2010US20100249082 Modulators of hypoxia inducible factor-1 and related uses
09/30/2010US20100249078 Tetracyclic inhibitors of fatty acid amide hydrolase
09/30/2010US20100249073 Prophylactic and therapeutic treatment of Alzheimer's disease using phytic acid and phytate to reduce amyloid beta plaque and tau protein
09/30/2010US20100249057 Trehalose compound and pharmaceutical comprising the compound
09/30/2010US20100249045 Multimodal Abuse Resistant and Extended Release Opioid Formulations
09/30/2010US20100249036 Method for treating depression
09/30/2010US20100249034 Gfralpha3 and its uses
09/30/2010US20100249032 Human EPO Mimetic Hinge Core Mimetibodies, Compositions, Methods and Uses
09/30/2010US20100249019 Use of a peptide as a therapeutic agent
09/30/2010US20100249017 Use of cnp-22, alone or in combination with physalemin, as a therapeutic agent
09/30/2010US20100249016 Metal-binding compounds and uses therefor
09/30/2010US20100247691 Anti-angiogenic agents and anti-obesity substances applied with anti-angiogenesis from natural products
09/30/2010US20100247688 Pirenzepine and derivatives thereof as anti-amyloid agents
1 ... 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 ... 1833